Clinical Edge Journal Scan

Sarcopenia and poor balance increase risk for vertebral spinal osteoporotic fracture in women with RA


 

Key clinical point: Sarcopenia and poor balance were associated with a higher risk for vertebral spinal osteoporotic fracture (VOPF), disease activity, and joint structure damage in women with rheumatoid arthritis (RA).

Major finding: Women with vs without RA had a significantly higher incidence of sarcopenia (60.0% vs 11.1%; P < .0001), poor balance (44.1% vs 7.9%; P < .0001), and VOPF (21% vs 3.2%; P < .0001). Among women with RA, those with vs without VOPF had a significantly higher incidence of sarcopenia (75.6% vs 55.8%; P < .0001) and poor balance (68.3% vs 37.7%; P < .0001) and those with vs without sarcopenia and poor balance had a higher disease activity, more serious joint damage, and worse joint function (all P < .05).

Study details: This study included 195 women with RA and 126 age- and sex-matched healthy individuals.

Disclosures: This study did not declare any source of funding . The authors declared no competing interests.

Source: Zhang M et al. Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis. Sci Rep. 2022;12:9477 (Jun 8). Doi: 10.1038/s41598-022-13339-2

Recommended Reading

Physicians urged to write indications on drug scripts as methotrexate users face new barriers with SCOTUS decision
MDedge Rheumatology
Feds warn pharmacists: Don’t refuse to provide abortion pills
MDedge Rheumatology
Neural networks can distinguish PsA from rheumatoid arthritis on MRI
MDedge Rheumatology
Methotrexate’s impact on COVID-19 vaccination: New insights made
MDedge Rheumatology
TNF inhibitor use for RA shows beneficial effect in pregnancy
MDedge Rheumatology
Menopausal status and use of sex hormones influence remission in female patients with RA
MDedge Rheumatology
Higher prevalence of CPPD and chondrocalcinosis in seronegative than seropositive RA
MDedge Rheumatology
Real-world efficacy and safety of second-line therapies for RA
MDedge Rheumatology
RA: Ozoralizumab shows promise in patients with inadequate response to methotrexate
MDedge Rheumatology
RA: Rapid improvements in patient-reported outcomes with upadacitinib vs abatacept
MDedge Rheumatology